284 related articles for article (PubMed ID: 31028182)
1. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
3. Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.
Köbel M; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Stewart CJR; Lee CH
Am J Surg Pathol; 2018 Jan; 42(1):76-83. PubMed ID: 28863077
[TBL] [Abstract][Full Text] [Related]
4. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
5. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
6. The Role of the AT-Rich Interaction Domain 1A Gene (
Li JJ; Lee CS
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
[TBL] [Abstract][Full Text] [Related]
7. ARID1A mutations in cancer: another epigenetic tumor suppressor?
Wu JN; Roberts CW
Cancer Discov; 2013 Jan; 3(1):35-43. PubMed ID: 23208470
[TBL] [Abstract][Full Text] [Related]
8. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
9. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
10. ARID1 and BRG1 Expression in Endometrial Cancer.
Kontomanolis EN; Symeonidis P; Nikolettos K; Perros P; Rody A; Tsikouras P; Nikolettos N; Giatromanolaki A
In Vivo; 2024; 38(3):1260-1265. PubMed ID: 38688602
[TBL] [Abstract][Full Text] [Related]
11. Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
Xing B; Zhang X; Gu X; Xiang L; Wang C; Jin Y
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17529-17541. PubMed ID: 37906351
[TBL] [Abstract][Full Text] [Related]
12. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
13. ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
Jin F; Yang Z; Shao J; Tao J; Reißfelder C; Loges S; Zhu L; Schölch S
Trends Mol Med; 2023 Aug; 29(8):646-658. PubMed ID: 37179132
[TBL] [Abstract][Full Text] [Related]
14. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
15. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Wilson MR; Reske JJ; Holladay J; Wilber GE; Rhodes M; Koeman J; Adams M; Johnson B; Su RW; Joshi NR; Patterson AL; Shen H; Leach RE; Teixeira JM; Fazleabas AT; Chandler RL
Nat Commun; 2019 Aug; 10(1):3554. PubMed ID: 31391455
[TBL] [Abstract][Full Text] [Related]
16. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
[TBL] [Abstract][Full Text] [Related]
17. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of mutated ARID1A inhibited endometrial cancer cell proliferation and stimulated cell apoptosis.
Ye Y; Wei B; Xiaowei X
J BUON; 2018; 23(4):1082-1091. PubMed ID: 30358215
[TBL] [Abstract][Full Text] [Related]
20. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]